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At the end of 2019 reports started to surface of a
novel viral infection that has become known as SARS-
CoV-2 (causing the infection COVID-19) and was
classified as a pandemic by the World Health Orga-
nization (WHO) in March 2020. Countries around the
world have utilised a range of measures to face this
pandemic and although each country has their own
unique approach, it has typically included periods of
self-isolation or quarantine to help limit both the
spread of the virus and the burden on health care
systems. During these periods of self-isolation, many
have been asking themselves what they can do to
help. There have been some uplifting reports of
everyone pulling together to do their part, whether
that is breweries, distilleries or perfume manufac-
turers making hand sanitiser, [4] or collaborative
teams of engineers and scientists working together to
produce and redesign ventilators [2].
But what could a materials chemist do to help?
Viruses are often thought of as being a problem to be
resolved by biologists and biochemists, yet in reality,
there are many crossovers with chemistry and
materials, ready to be exploited [11].
Viruses are intracellular parasites with a very
simple structure. They lack their own metabolism
and require a host to replicate, so are (debatably) not
living [8]. Instead viruses can be thought of as self-
assembled nanostructures, typically comprised of
proteins, genetic material, and often a lipid mem-
brane. Prof. Palli Thordarson (Department of Chem-
istry, The University of New South Wales (UNSW))
recently highlighted this in a Twitter thread [13],
showing why it is so important to use soap when
washing your hands to destroy viruses like SARS-
CoV-2.
The key characteristic behind why soap is so
effective is linked directly to the fact that viruses are
self-assembled structures. Their lipid membranes are
comprised of fatty acids with hydrophobic interac-
tions between chains, leading to a stable outer
membrane. When you introduce soap into the mix-
ture these hydrophobic interactions are disrupted
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and the lipid membrane is ‘dissolved’, destroying or
deactivating the virus. Materials capable of destroy-
ing a virus in such a way are termed virucidal (Fig. 1)
and there are many examples: bleach, alcohol and, as
already mentioned, soap. This is a simple approach to
destroying a virus and it is widely used in many
areas from virology labs, (Virkon—used to sterilise
and decontaminate surface) through to hospitals (al-
cohol hand gel). Yet, it is not possible to use soap (or
other virucides) as an internal treatment because the
exact same process that destroys the virus would also
destroy our own cells.
On the topic of treatment options for viruses, there
are two main approaches to antivirals, intracellular
and extracellular, both of which can benefit greatly
from input from materials chemists.
Intracellular antivirals are almost exclusively
small-molecule drugs that are designed to inhibit the
intracellular replication of viruses, for example some
of the promising candidates for treating SARS-CoV-2:
Remdesivir (Fig. 2), which was originally developed
for Ebola [14], and Kaletra (ritonavir and lopinavir
combination), originally designed for HIV [1].
As with the majority of these intracellular drugs,
they are designed to be effective against a specific
virus and although they may be effective against
other viruses, there are no guarantees. To ensure
success, each drug would need to redesigned using,
for example, in silico studies or a process of trial and
error; however, this would mean a re-design for
every viral outbreak. An intracellular approach does
not readily lend itself towards a broad-spectrum
drug, because each virus utilises a different replica-
tion pathway to multiply.
A broad-spectrum antiviral, similar to broad-
spectrum antibiotics, would rapidly treat newly
emerging viral outbreaks. Extracellular antivirals,
unlike intracellular antivirals, become important here
as they have potential to be the most broad spectrum.
There are many types of extracellular antivirals, but
the most common are ‘entry inhibitors’—another area
where materials chemists can get their hands dirty.
Entry inhibitors are, in general, materials that bind
to the virus surface and block the interactions with
the host cells, thereby stopping the virus from being
able to infect. As different viruses can use the same
(or similar) initial attachment receptors on the surface
of cells [5]; these entry inhibitors can be designed to
mimic such receptors. In doing so, these materials
show broad-spectrum activity with other viruses that
use the same initial attachment receptors.
In principal, these sound like our best approach;
however, the interaction between material and virus
can be reversible (termed virustatic) and so with a
simple change in dilution, pH or temperature the
infective virion would be released. There have been
many examples of broad-spectrum virustatic mate-
rials including polymers [9, 12], dendrimers [10], and
nanoparticles [3] and all show very low levels of
toxicity. Yet, when it comes to their use as a treat-
ment, these virustatic materials fall short because in
the in vivo environment dilution occurs readily,
leading to release of the intact virion [12].
What if we could take these non-toxic, broad-
spectrum entry inhibitors, modify them and change
their mode of action from virustatic to virucidal? This
change would lead to a material that was able to
destroy a wide range of viruses on contact (i.e. broad
spectrum) while remaining non-toxic. This might
sound too good to be true, but my colleagues and I
recently discovered materials capable of doing just
that [6, 7].
By modifying a sugar macrocycle, called
cyclodextrin, with alkyl sulfonates, we were able to
show broad-spectrum virucidal effects against viru-




















Figure 2 Chemical structure of Remdesivir, a potential antiviral
candidates for treatment of COVID-19.
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initial attachment receptors (Fig. 3). These include,
but are not limited to, human immunodeficiency
virus (HIV) (EC50 ¼ 3:35 lM), herpes simplex virus 1
(HSV-1) (EC50 ¼ 15:3 lM), herpes simplex virus 2
(HSV-2) (EC50 ¼ 8:61 lM), respiratory syncytial virus
A (RSV-a) (EC50 ¼ 2:99 lM), Dengue virus
(EC50 ¼ 4:63 lM), Zika virus (EC50 ¼ 0:2 lM) and
hepatitis C (EC50 ¼ 2:04 lM). As well as being broad
spectrum, these modified cyclodextrins were viruci-
dal and showed very low toxicity in vitro. We
observed that the linker length between the
cyclodextrin backbone and the sulfonate group was
critical for achieving this virucidal mechanism, with
shorter alkyl linkers leading to poorer EC50’s and
loss of the virucidal mechanism.
Through the use of molecular dynamic simula-
tions, we show that upon binding of the modified
cyclodextrins to the attachment receptor of the HSV2
virus, the protein trimer is altered only in the pres-
ence of the virucidal cyclodextrin variant.
Initial tests of these antivirals against SARS-CoV-2
has shown promising efficacy, but further tests are
needed to confirm this finding. The key now is to try
and develop these types of materials, not only for
clinical use in the fight against SARS-CoV-2 (if nee-
ded), but also ultimately so that they are ready for the
next inevitable viral outbreak.
This represents only one example of a material-
based approach that can be used in the fight against
viral infections. There are many other avenues
waiting to be explored (such as antiviral face masks
or antiviral surfaces) that offer materials chemists
further opportiunities to apply their expertise to the
virus problem.
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[7] Jones ST, Cagno V, Janeček M, Ortiz D, Gasilova N, Piret J,
Gasbarri M, Constant DA, Han Y, Vuković L, Král P, Kaiser
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